KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Depreciation and Depletion (2020 - 2024)

Aurinia Pharmaceuticals (AUPH) has disclosed Depreciation and Depletion for 5 consecutive years, with -$14.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Depreciation and Depletion fell 129.3% year-over-year to -$14.0 million, compared with a TTM value of $600000.0 through Dec 2024, changed 0.0%, and an annual FY2025 reading of $600000.0, changed 0.0% over the prior year.
  • Depreciation and Depletion was -$14.0 million for Q4 2024 at Aurinia Pharmaceuticals, down from $4.9 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $5.3 million in Q3 2023 and bottomed at -$14.0 million in Q4 2024.
  • Average Depreciation and Depletion over 5 years is $145588.2, with a median of $688000.0 recorded in 2021.
  • The sharpest move saw Depreciation and Depletion skyrocketed 5633.33% in 2021, then tumbled 223.16% in 2023.
  • Year by year, Depreciation and Depletion stood at $12000.0 in 2020, then crashed by 11491.67% to -$1.4 million in 2021, then plummeted by 38.04% to -$1.9 million in 2022, then crashed by 223.16% to -$6.1 million in 2023, then plummeted by 129.3% to -$14.0 million in 2024.
  • Business Quant data shows Depreciation and Depletion for AUPH at -$14.0 million in Q4 2024, $4.9 million in Q3 2024, and $4.8 million in Q2 2024.